key: cord-0263970-xgsmgscj
authors: Ma, Shoubao; Yan, Jiazhuo; Barr, Tasha; Zhang, Jianying; Chen, Zhenhua; Wang, Li-Shu; Sun, Joseph C.; Chen, Jianjun; Caligiuri, Michael A; Yu, Jianhua
title: The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity
date: 2021-04-27
journal: bioRxiv
DOI: 10.1101/2021.04.26.441557
sha: 4fb264594aef8b18f6b19436420af74d14042c4f
doc_id: 263970
cord_uid: xgsmgscj

N6-methyladenosine (m6A) is the most prevalent post-transcriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate anti-viral and anti-tumor immunity. However, whether and how m6A modifications affect NK cell immunity remains unknown. Here, we discover that YTHDF2, a well-known m6A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell anti-tumor and anti-viral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15-mediated NK cell survival and proliferation by forming a STAT5-YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m6A modifications in NK cells and highlight a new direction to harness NK cell anti-tumor immunity.

Natural killer (NK) cells are the predominant innate lymphoid cells (ILC) that mediate anti-viral and anti-tumor immunity (Spits et al., 2016) . They recognize virus-infected and cancerous cells through their multiple surface-expressed activating and inhibitory receptors and kill them via a cytotoxic effect . They can also produce a distinct set of cytokines such as IFN-γ, TNF-α, IL-10, or chemokines such as MIP-1α and -β and RANTES, which can further elicit adaptive immune responses (Spits et al., 2016) . Together, the multifunctional activities of NK cells help to eliminate susceptible targets and amplify inflammatory responses against viruses and cancer.

As the most prevalent post-transcriptional modification on mammalian mRNA, the N 6methyladenosine (m 6 A) modification is emerging as a widespread regulatory mechanism that controls gene expression in diverse physiological processes (Yue et al., 2015) . However, how m 6 A methylations regulate innate and adaptive cell-mediated immunity remains to be fully understood and, up until this report, has remained unknown in NK cells. Recently, chimeric antigen receptors (CARs) have been shown to re-direct NK cells toward tumor cells expressing a corresponding antigen, creating opportunities to fight against cancer (Chen et al., 2016; Chu et al., 2014; Han et al., 2015; Liu et al., 2020; Tang et al., 2018; Yilmaz et al., 2020) . Therefore, clearly defining the role of m 6 A modification in NK cells will not only greatly improve our understanding of RNA modifications as a novel and critical layer of post-transcriptional gene regulation that controls innate immune cell functions but may also provide us a new opportunity to enhance NK cell effector function and survival for cancer immunotherapy.

The m 6 A methyltransferases ("writers", i.e., METTL3 and METTL14) and demethylases ("erasers", i.e., FTO and ALKBH5) dynamically control the m 6 A methylation landscape within the nucleus (Shi et al., 2019) . The m 6 A reader proteins (YTH domain-containing family (YTHDF) proteins, YTHDF1, YTHDF2, and YTHDF3; and insulin-like growth factor 2 mRNAbinding (IGF2BP) proteins, IGF2BP1, IGF2BP2, and IGF2BP3) preferentially bind to the methylated RNA and mediate specific functions, including promoting the translation or affecting stability of m 6 A-modified mRNAs Shi et al., 2019; Wang et al., 2014; Wang et al., 2015) . Recent studies have shown that m 6 A methylation is involved in adaptive and innate immune cell-mediated immunity (Shulman and Stern-Ginossar, 2020) .

3 Deletion of m 6 A "writer" protein METTL3 in mouse T cells disrupts cell homeostasis and differentiation by targeting the IL-7/SOCS/STAT5 pathway (Li et al., 2017) . METTL3 maintains Treg cell suppressive functions through IL-2-STAT5 signaling (Tong et al., 2018) . RNA m 6 A methylation plays an essential role in early B cell development (Zheng et al., 2020) . A recent report shows that METTL3-mediated mRNA m 6 A methylation promotes dendritic cell (DC) activation (Wang et al., 2019a) . m 6 A-modified mRNAs encoding lysosomal cathepsins can be recognized by YTHDF1 in DCs, thereby suppressing the cross-priming ability of DCs and inhibiting anti-tumor immune responses (Han et al., 2019) . m 6 A modifications also control the innate immune response to virus infection Rubio et al., 2018; Winkler et al., 2019) . However, whether and how m 6 A modifications affect the NK cell-mediated immune response to tumor cells and virus has not been reported.

YTHDF2 is a well-recognized m 6 A reader that acts by specifically recognizing and binding to m 6 A-containing RNAs and promoting degradation of target transcripts (Wang et al., 2014) .

According to the database of BioGPS (Wu et al., 2013) and our preliminary data, murine NK cells express YTHDF2 at a high level, while its role in regulating NK cells is unknown. This motivates us to study YTHDF2 in NK cells using a conditional knockout approach. We show that depletion of Ythdf2 in mouse NK cells significantly impaired NK cell anti-tumor and antiviral immunity. Moreover, YTHDF2 controlled NK cell homeostasis, maturation, and survival at a steady state. Thus, YTHDF2 or m 6 A in general plays multifaceted roles in regulating NK cells.

To study the role of m 6 A modifications in NK cells, we first screened the expression levels of m 6 A "writers", "erasers", and "readers" in murine NK cells by using BioGPS database (http://biogps.org). Accordingly, the expression of Ythdf2 mRNA was the highest among the other m 6 A enzymes and readers ( Fig. 1 A) . Interestingly, we found that NK cells also have constitutive mRNA and protein expression of Ythdf2 at high levels compared to most other immune cells, including B cells, macrophages, and DCs ( Fig. 1 B and Fig. S1 A) . NK cells can be activated by IL-15, which is a key regulator of NK cell homeostasis and survival (Becknell and Caligiuri, 2005) . Leveraging the GEO database, we found that IL-15-activated NK cells have higher mRNA levels of Ythdf2 compared to other m 6 A enzymes and readers that we tested (Fig. 1 C, analyzed from GSE106138). Consistent with our analysis of the BioGPS data, our real-time quantitative PCR (qPCR) and immunoblotting showed that IL-15 activation of NK cells significantly upregulated Ythdf2 at both the mRNA and protein levels, and that Ythdf2 seemed to have the highest expression levels in IL-15-activated NK cells compared to other m 6 A enzymes and readers that we tested (Fig. 1, and Fig. S1 B) . The protein levels of YTHDF2 were also significantly upregulated in NK cells from IL-15Tg mice that we previously generated compared to wild-type control (Fehniger et al., 2001) (Fig. S1 C) .

NK cells are critical mediators of host immunity against viral infection and malignancies (Spits et al., 2016) . We therefore evaluated the expression pattern of YTHDF2 in NK cells during murine cytomegalovirus (MCMV) infection. Using the GEO database, we found that Ythdf2 was upregulated at day 1.5 post-infection in two independent databases (Fig. 1 G and Fig. S1 D) . An immunoblotting assay confirmed that the protein levels of YTHDF2 were also upregulated at day 1.5 post-infection with MCMV ( Fig. S1 E) , indicating that YTHDF2 may play a critical role in NK cell-mediated anti-viral immunity. In addition to controlling virus infection, NK cells also contribute to anti-tumor immunosurveillance. We then examined the Ythdf2 levels during tumor development. Using the B16F10 melanoma metastasis model, we found a reduction of NK cells in the lung at the late stage of tumor development (Fig. S1 F) , which is consistent with a prior report (Cong et al., 2018) . We found that the mRNA and protein 5 levels of Ythdf2 were significantly upregulated in NK cells at the early stage of tumor development ( Fig. 1 H and Fig. S1 G) . Taken together, these data demonstrate that Ythdf2 is highly expressed in NK cells and is upregulated during viral infection and tumorigenesis, leading us to hypothesize that YTHDF2 plays a role in regulating NK cell defense against tumorigenesis and viral infection.

To define the role of YTHDF2 in NK cell-mediated anti-tumor immunity, we used the CRISPR-Cas9 technology to generate Ythdf2 floxed mice (Fig. S1 H) . We then generated NK cell-specific conditional knockout mice (hereafter referred to as Ythdf2 ∆ NK mice displayed a much greater burden of metastatic nodules than that of Ythdf2 WT mice. We found a significant reduction in the percentage and absolute number of infiltrating NK cells in tumor tissues of Ythdf2 ∆ NK mice compared to those observed in Ythdf2 WT mice (Fig. 2 , B and C). Meanwhile, infiltrating NK cells from Ythdf2 ∆ NK mice showed a significant decrease in the expression of IFN-γ, granzyme B, and perforin compared with those from Ythdf2 WT mice (Fig. 2 , D-F). However, the percentages of CD4 + T cells and CD8 + T cells and their expression of IFN-γ were comparable between Ythdf2 WT mice and Ythdf2 ∆ NK mice (Fig. S1, K-N), suggesting that YTHDF2 in NK cells is essential for controlling tumor metastases. To confirm the cell-intrinsic requirement of YTHDF2 for NK cell-mediated anti-tumor immunity, we adoptively transferred an equal number of NK cells from Ythdf2 ∆ NK mice or Ythdf2 WT mice into Rag2 −/− Il2rg −/− mice which lack T, B, and NK cells, one day prior to an injection of B16F10 tumor cells (Fig. 2 G) . We found a significantly increased incidence of tumor metastases in mice transferred with Ythdf2 ∆ NK NK cells compared with mice injected with Ythdf2 WT NK cells (Fig. 2 G). Similarly, in this model, we also found a significant reduction in the percentage and the absolute number of infiltrating Ythdf2 ∆ NK NK cells (Fig. 2 , H and I), as well as a decrease in the expression of IFN-γ, granzyme B, and perforin in mice that received adoptively transferred Ythdf2 ∆ NK NK cells compared to those that received Ythdf2 WT NK cells (Fig. 2 , J-L). These data indicate a cell-intrinsic role of YTHDF2 in the regulation of NK cell anti-tumor immunity.

To determine whether Ythdf2 deficiency affects the anti-viral activity of NK cells, we injected 2.5×10 4 plaque-forming units (pfu) of MCMV into Ythdf2 WT mice and Ythdf2 ∆ NK mice. The results showed that Ythdf2 ∆ NK mice were more susceptible to MCMV infection, as depicted by significant weight loss and increased viral titers in blood, spleen, and liver compared to Ythdf2 WT mice (Fig. 3, A and B; and Fig. S2, A and B) . We also observed a significant reduction in the percentage and the absolute number of total NK cells in spleen and blood of Ythdf2 ∆ NK mice compared to those in Ythdf2 WT mice post-infection (Fig. 3, C and D; and Fig. S2, C and D) .

Further analysis showed that NK cells from Ythdf2 ∆ NK mice had significantly lower expression of Ki67 than that of Ythdf2 WT mice (Fig. 3 , E-G). However, NK cell viability was similar in Ythdf2 WT mice and Ythdf2 ∆ NK mice, as shown by Annexin V staining (Fig. S2 E) . These data indicate the deficiency of YTHDF2 in NK cells results in a defect in cell proliferation rather than cell survival during viral infection. NK cells inhibit MCMV infection through the activating receptor Ly49H and Ly49D and are characterized by a perforin-or IFN-γ-mediated anti-viral response (Arase et al., 2002; Lee et al., 2009; Loh et al., 2005; Orr et al., 2010; Sumaria et al., 2009 ). We found that Ythdf2 ∆ NK mice had significantly reduced Ly49H + and Ly49D + NK cells in spleen and blood compared to that of Ythdf2 WT mice post-infection (Fig. 3 S2, X and Y). We found significantly reduced perforin production by Ythdf2 ∆ NK mice compared to that of Ythdf2 WT mice in both spleen and blood 7 days post-infection (Fig. 3 , K-M), indicating that YTHDF2 mainly affects perforin-mediated anti-viral activity against MCMV in NK cells.

These data indicate that YTHDF2 is critical for NK cell expansion and effector function during MCMV infection.

The above findings that Ythdf2 deficiency in NK cells enhanced tumor metastases and impaired NK capacity to control MCMV infection encouraged us to investigate whether YTHDF2 was required for NK cell maintenance at a steady state. As shown in Fig. 4 A, the frequency and the absolute number of NK cells were significantly reduced in the peripheral blood, spleen, liver, and lung but not bone marrow (BM) in Ythdf2 ∆ NK mice compared with Ythdf2 WT mice. However, there were no significant changes among common lymphoid progenitor (CLP), pre-NK cell progenitor (preNKP), and refined NKP (rNKP) in the BM (Fathman et al., 2011) between Ythdf2 WT and Ythdf2 ∆ NK mice (Fig. S3 A) , indicating that YTHDF2 may not affect NK cell early development in our model. To explore the potential mechanisms responsible for the decrease of NK cells in Ythdf2 ∆ NK mice, we investigated cell proliferation, viability, and trafficking ability of NK cells after Ythdf2 deletion at a steady state. The percentage of proliferating NK cells was comparable between Ythdf2 WT and Ythdf2 ∆ NK mice, as evidenced by Ki67 staining (Fig. S3 B) .

The viability of NK cells was also equivalent between Ythdf2 WT and Ythdf2 ∆ NK mice, as shown by Annexin V staining (Fig. S3 C) . To check whether YTHDF2 affects egress of NK cells from BM to the periphery, Ythdf2 WT and Ythdf2 ∆ NK mice were intravenously injected with an anti-CD45 antibody to mark immune cells, sacrificed after 2 min, and their BM cells were analyzed. This allowed us to quantify the number of NK cells in the sinusoidal versus parenchymal regions of the BM, an indicator of NK cell trafficking from BM to peripheral blood under a steady state (Leong et al., 2015) . The results showed a significant reduction in the frequency of CD45 + NK cells in Ythdf2 ∆ NK mice compared to Ythdf2 WT mice in the sinusoids (Fig. 4 

Ythdf2 deficiency impairs the egress of NK cells from bone marrow to the circulation system in vivo.

Immune cells undergo homeostatic proliferation during lymphopenia induced by certain viral infections or caused by chemotherapy . Although we found YTHDF2 is dispensable for NK cell proliferation at a steady state, we observed a significant decrease in cell proliferation during MCMV infection (Fig. 3 , E-G). We, therefore, investigated the role of YTHDF2 in regulating NK cell homeostatic proliferation in a lymphopenic setting in vivo. We co-transferred an equal number of splenic NK cells from CD45.2 Ythdf2 ∆ NK mice or CD45.1 congenic mice into lymphocyte-deficient Rag2 −/− Il2rg −/− mice. The results showed a greater proportion of NK cells were derived from CD45.1 WT control mice than from CD45.2 Ythdf2 ∆ NK mice day 3 after cell transfer (Fig. S3 D) . Further analysis demonstrated that the reduction of NK 8 cells from Ythdf2 ∆ NK mice was due to impaired cell proliferation (Fig. S3 E) but not cell apoptosis ( Fig. S3 F) , suggesting that YTHDF2 drives NK cell homeostatic proliferation in vivo under lymphopenic conditions. Further differentiation of murine NK cells can be classified into immature (CD11b − CD27 + ), intermediate mature (CD11b + CD27 + ), and terminal mature (CD11b + CD27 − ) stages based on CD11b and CD27 levels (Chiossone et al., 2009; Geiger and Sun, 2016) . We found that Ythdf2 expression increased with maturation and CD11b − CD27 + , CD11b + CD27 + , CD11b + CD27 − and display lowest, intermediate, and highest expression levels of Ythdf2, respectively ( Fig. S3 G) , indicating that YTHDF2 may be involved in NK cell maturation. We, therefore, investigated the role of YTHDF2 in NK cell maturation defined by the cell surface markers CD11b and CD27.

We found that loss of Ythdf2 in NK cells resulted in a significant decrease in the frequency of positively regulates terminal NK cell maturation. Consistent with these data, the levels of KLRG1, which is a terminal NK cell maturation marker, were significantly lower in Ythdf2 ∆ NK mice in the spleen, liver, and lung but not BM compared to that of Ythdf2 WT mice in the corresponding organs or tissue compartments (Fig. 4 D) . To determine whether the decreased number of mature NK cells by Ythdf2 deficiency is cell-intrinsic, we created chimeras in (Daussy et al., 2014; Gordon et al., 2012) . Intracellular staining revealed a significant reduction in the protein levels of Eomes in NK cells from Ythdf2 ∆ NK mice compared with Ythdf2 WT mice (Fig. S3 I) . In addition, we found that the reduction of protein and mRNA levels of Eomes specifically occurred in terminal mature (CD11b + CD27 − ) NK cells (Fig. S3 , J-L).

However, in contrast to Eomes, the expression of Tbet was equivalent in NK cells between 

Our finding that Ythdf2 deficiency impeded NK cell homeostasis and maturation motivated us to determine if YTHDF2 also repressed NK cell effector function. The major mechanism that regulates NK cell function is the relative contribution of inhibitory and activating receptors (Chan et al., 2014) . We then checked the expression levels of molecules associated with NK cell activation or inhibition. We found that the expression levels of the activating receptors CD226 and NKG2D, but not CD69, were decreased in splenic NK cells from Ythdf2 ∆ NK mice compared with those of Ythdf2 WT mice ( Fig. 5 A) , whereas the inhibitory receptors NKG2A, TIGIT, and PD-1 were similar between Ythdf2 is essential for NK cell effector function.

YTHDF2 is required for IL-15-mediated NK cell survival, proliferation, and effector functions IL-15 is one of, if not the most important cytokine for pleiotropic functions of NK cells. We and others previously discovered that IL-15 plays key roles in regulating NK cell homeostasis, survival, and effector functions (Becknell and Caligiuri, 2005; Carson et al., 1997; Carson et al., 1994; Wang et al., 2019b; Yu et al., 2013) . In the current study, we showed that IL-15 upregulated mRNA and protein levels of YTHDF2 in NK cells ( Fig. 6A and Fig. 1 , D-F).

Therefore, we speculated that YTHDF2 is required for IL-15-mediated survival and effector functions of NK cells. We first attempted to identify potential transcription factors downstream of IL-15 signaling that directly regulate YTHDF2 expression. We analyzed the ENCODE using the University of California Santa Cruz (UCSC) Genome Browser Database (https://genome.ucsc.edu), which provides predictions of binding sites across the entire genome, in combination with JASPAR (http://jaspar.genereg.net). We found that STAT5, which is a key 1 0 transcription start site (TSS) of Ythdf2, indicating that IL-15 may positively regulate Ythdf2 transcription in mouse NK cells through STAT5. By utilizing STAT5 inhibitor, STAT5-IN-1 (Muller et al., 2008) , we showed that inhibition of STAT5 resulted in a decrease of Ythdf2 at both mRNA and protein levels in murine NK cells (Fig. S4, A and B) . To further confirm YTHDF2 is a downstream factor regulated by STAT5, we used Stat5 fl/fl Ncr1-iCre mice (hereafter referred to as Stat5 ∆ NK mice), where STAT5 is specifically deleted in mouse NK cells (Wiedemann et al., 2020) . We treated splenic NK cells from Stat5 WT and Stat5 ∆ NK mice with IL-15. We found that YTHDF2 substantially decreased in NK cells from Stat5 ∆ NK mice compared to NK cells from Stat5 WT mice at both the mRNA and protein levels ( We then wondered whether Ythdf2-deficient NK cells were defective in their response to IL-15. We isolated splenic NK cells from Ythdf2 ∆ NK mice and Ythdf2 WT mice and cultured in vitro in the presence of IL-15. We found that NK cell growth was significantly decreased in Ythdf2 ∆ NK mice compared to Ythdf2 WT mice ( Fig. 6 G) . CellTrace Violet labeling assay showed that the proliferation of NK cells was impaired by Ythdf2 deficiency (Fig. 6 H) . Cell cycle distribution analysis revealed a significantly increased fraction of NK cells from Ythdf2 ∆ NK mice in G 0 /G 1 phase but a significantly decreased fraction of NK cells from Ythdf2 ∆ NK mice in S phase ( Fig. 6 I), suggesting Ythdf2 deficiency results in G 0 /G 1 phase arrest in NK cells. In addition, there was a two-to three-fold increase in apoptotic (Annexin V + Sytox-Blue +/− ) NK cells from Ythdf2 ∆ NK mice compared to those from Ythdf2 WT mice ( Fig. 6 J) , indicating the defective survival of NK cells after the loss of Ythdf2. These results suggest that YTHDF2 regulates the responsiveness of NK cells to IL-15 in vitro. Since IL-15 is poorly translated and secreted in vivo at a steady-state (Corbel et al., 1996; Fehniger et al., 2001) , to explore whether Ythdf2-deficient NK cells are defective in their response to IL-15 in vivo, we treated mice with IL-15. We found that Ythdf2deficient vs. WT NK cells showed significantly reduced cell proliferation and increased cell apoptosis when mice were treated with IL-15 ( Fig. 6 K and Fig. S4 , E-J). These data suggest that 1 1 with a high level of IL-15. We also found that the mRNA and protein levels of IFN-γ, granzyme B, and perforin were significantly reduced in Ythdf2 ∆ NK NK cells compared with Ythdf2 WT NK cells in response to , indicating that YTHDF2 also contributes to IL-15mediated NK cell effector functions in vitro. Collectively, our data demonstrate that YTHDF2 is required for IL-15-mediated NK cell survival, proliferation, and effector functions.

Next, we investigated the downstream mechanisms by which YTHDF2 regulates IL-15mediated NK survival, proliferation, and effector function. We found that NK cells from 

To address the molecular mechanism by which YTHDF2 regulates NK cells, we first performed RNA-seq in IL-2-expanded Ythdf2 WT and Ythdf2 B). Cell cycle and division-related genes, including Aurka, Aurkb, Cdc20, Cdc25b, Cdc25c, Cdk1, E2f2, and Plk1 (Bertoli et al., 2013) , were significantly decreased in NK cells from Ythdf2 ∆ NK mice (Fig. 7 B ). Spindle and chromosome segregation genes such as Anln, Aspm, Birc5, Bublb, Cenpe, Esco2, Ska1, Ska3, and Tpx2 (Gorbsky, 2015) , were also significantly downregulated in NK cells from Ythdf2 ∆ NK mice compared to NK cells from Ythdf2 WT mice (Fig. 7 C) . In addition, cell survival genes, including Birc5 (Niu et al., 2010) , Septin4 (Larisch et al., 2000) , and Rffl (Yang et al., 2007) were significantly decreased in NK cells from Ythdf2 ∆ NK mice ( Fig. 7 D) . NK cell effector function genes, including Klrk1, Ncr1, CD226, and Gzma (Bezman et al., 2012) , were also significantly downregulated in NK cells from Ythdf2 ∆ NK mice (Fig. 7 D) .

These data support our characterized roles of YTHDF2 in regulating NK proliferation, survival, and effector functions.

We then performed m 6 A-seq in IL-2 expanded NK cells from Ythdf2 WT and Ythdf2 It is well known that YTHDF2 acts as an m 6 A reader, which recognizes and binds m 6 Acontaining RNAs and regulates the degradation of m 6 A transcripts. We then performed RNA immunoprecipitation sequencing (RIP-Seq) using YTHDF2 antibody to map the target transcripts bound by YTHDF2 in NK cells. YTHDF2-binding sites were enriched in the proteincoding sequence and 3'UTR regions (Fig. S5 , E and F). We identified 3951 potential YTHDF2 binding peaks from 1290 transcripts, 426 (33%) of which were detected with significant m 6 A enrichment. GO enrichment analysis showed that the YTHDF2 target 1290 transcripts were 1 3

We then identified the potential target transcripts from overlapping transcripts through the RNA-seq, m 6 A-seq, and RIP-seq and found a set of 29 transcripts bound by YTHDF2, marked with m 6 A (in both Ythdf2 WT and Ythdf2 ∆ NK NK cells) were differentially expressed between NK cells from Ythdf2 WT and Ythdf2 ∆ NK mice (Fig. 7 G) . Among them, 12 transcripts were upregulated, and 17 transcripts were downregulated in NK cells from Ythdf2 ∆ NK mice compared to those from Ythdf2 WT NK cells (Fig. 7 G) . Based on our functional characterization of YTHDF2 and the GO analysis from the RNA-seq data, Ythdf2 deficiency affects NK cell division and proliferation, possibly by facilitating mRNA degradation of cell cycle checkpoints or negative regulators during cell division. Among the 12 upregulated transcripts, three of them have been reported to negatively regulate cell division or proliferation, including, Mdm2 (murine double minute 2, MDM2) (Frum et al., 2009; Giono and Manfredi, 2007; Giono et al., 2017) , Tardbp (TAR DNA-binding protein 43, TDP-43) (Ayala et al., 2008; Sanna et al., 2020) , and Crebzf (CREB/ATF BZIP Transcription Factor, CREBZF) (Hu et al., 2020; Lopez-Mateo et al., 2012) , suggesting that they are the potential targets of YTHDF2 in NK cells. Of note, the m 6 A peaks fit well with the YTHDF2-binding sites at 3'UTR region of Mdm2 and Tardbp, and with the 5'UTR region of Crebzf genes, as shown by Integrative Genomics Viewer (Fig. 7 H) . RIP using either m 6 A or YTHDF2 antibody following qPCR confirmed that Mdm2, Tardbp, and 

In this study, we reported the multifaceted roles of YTHDF2-mediated m 6 A methylation in NK cell immunity. We found that YTHDF2, one of the most important readers of m 6 A modifications, was critical for maintaining NK cell homeostasis, maturation, IL-15-mediated survival, as well as anti-tumor and anti-viral activity. We also identified a novel positive feedback loop between STAT5 and YTHDF2, downstream of IL-15 that contributes to effector functions and survival in mouse NK cells. Our study elucidates the biological roles of YTHDF2 or m 6 A methylations in general in NK cell innate immunity. It fills in the gap of knowledge as to how YTHDF2 regulates the innate immune response to malignant transformation and viral infection. Our findings provide a new direction to harness the NK cell anti-tumor immunity and simultaneously advance our understanding of the m 6 A modifications in shaping innate immunity.

The m 6 A reader protein YTHDF2 regulates the stability of target mRNAs (Du et al., 2016; Wang et al., 2014) . Numerous studies have supported the broad impact of YTHDF2 in various biological processes. YTHDF2 suppresses normal hematopoietic stem cell (HSC) expansion and self-renewal but is also required for long-term HSC maintenance Mapperley et al., 2020; Paris et al., 2019; Wang et al., 2018a) . Recently, this gene has been found to be involved in restraining inflammation during bacterial infection (Wu et al., 2020a) . The role and mechanism of YTHDF2 in tumor development have been well-studied. YTHDF2 promotes leukemic stem cell development and acute myeloid leukemia (AML) initiation (Paris et al., 2019) . Besides leukemia, YTHDF2 has been shown to promote the development of solid tumors, including prostate cancer , glioblastoma (Dixit et al., 2020) , and hepatocellular carcinoma Hou et al., 2019; by targeting diverse m 6 Amodified transcripts, such as tumor suppressors LHPP and NKX3-1 , IGFBP3 (Dixit et al., 2020) , OCT4 , and SOCS2 . Although YTHDF2 plays a promoting role in tumor progression, our study reveals a beneficial role of YTHDF2 in the immune response to tumor cells, particularly in NK cells, which is a key should consider its potential effect acting on tumor cells directly. Differential targeting of YTHDF2 in tumor cells and in immune cells should maximize anti-tumor activity.

release of cytotoxic molecules such as perforin and granzymes that directly induce target cell apoptosis or pyroptosis (Zhou et al., 2020) ; 2) secretion of several cytokines such as IFN-γ, TNFα , granulocyte macrophage colony-stimulating factor (GM-CSF), and chemokines (MIP-1α, MIP-1β, IL-8, and RANTES) that enhance the function of other innate and adaptive immune cells (Fauriat et al., 2010; Reiter, 1993) . In this study, we observed non-identical mechanisms by which YTHDF2 regulates NK cell anti-tumor and anti-viral immunity. In the tumor setting, YTHDF2 promotes the secretion of perforin, granzyme B, and IFN-γ by NK cells for controlling melanoma metastasis, whereas during MCMV infection, YTHDF2 promotes NK cell-mediated anti-viral activity against MCMV mainly through regulating perforin. One potential explanation for this discrepancy is that NK cell activation by tumor or virus is regulated in different manners.

MCMV activates NK cells by encoding protein m157, a ligand of NK cell receptor Ly49H (Smith et al., 2002) , and associates with two intracellular adaptors, DAP10 and DAP12 (French et al., 2006; Orr et al., 2009) . However, in the tumor context, NK cell activation is tightly regulated by its interaction with different NK cell receptor ligands expressed by tumor cells, as well as the cytokines such as IL-15 and TGF-β in the tumor microenvironment (Wu et al., 2020b) . In addition, we found that YTHDF2 promotes NK cell maturation by regulating Eomes.

However, no binding sites were found in Eomes mRNA, suggesting that YTHDF2 indirectly regulates Eomes expression. Further studies are warranted to investigate the mechanism by which YTHDF2 regulates Eomes expression. In addition, how the YTHDF2 receives and mediates signals can quickly shape the NK cell immune response against virus or tumor cells differently also requires further exploration.

Adoptive transfer of allogeneic NK cells into leukemia patients can lead to remission (Ruggeri et al., 2002; Yilmaz et al., 2020) . Chimeric antigen receptor (CAR)-engineered NK cells have been shown to provide significant benefits in relapsed or refractory CD19-positive lymphoma and leukemia . However, limited expansion and persistence of NK cells in vivo, as well as limited NK cell trafficking and infiltration into tumor sites remain a major challenge for NK cell-based therapy (Yilmaz et al., 2020) . Since cancer patients or virally-1 7 infected patients, such as those with COVID-19, usually undergo transient lymphopenia (Grossman et al., 2015; Zhao et al., 2020) , efficient expansion of NK cells during lymphopenia is critical for controlling tumor growth and viral infection. Our findings show that YTHDF2 drives NK cell egress from BM and promotes NK cell homeostatic proliferation during lymphopenia in vivo in mice lacking T, B, and NK cells. Our study also shows that YTHDF2 positively regulates NK cell effector function. Therefore, incorporation of YTHDF2 expression into NK or CAR-NK cells may have multifaceted benefits for NK cell expansion during manufacturing in vitro, persistence, and enhancement of effector function in vivo. Furthermore, the upregulation of YTHDF2 that we observed in the tumor setting and during viral infection may increase the ability of NK or CAR-NK cells to infiltrate into the disease microenvironment.

IL-15 is a key regulator of NK cell development, homeostasis, survival, and effector function (Becknell and Caligiuri, 2005; Mishra et al., 2014; Yu et al., 2013) . Our group previously reported a novel IL-15-AKT-XBP1s signaling pathway that contributes to the effector functions and survival of human NK cells (Wang et al., 2019b) . However, the exact mechanism(s) by which IL-15 regulates NK cell survival has not yet been fully understood. Here we found another novel mechanism in that STAT5-YTHDF2 forms a positive feedback loop downstream of IL-15 in mouse NK cells that in turn controls NK cell proliferation, survival, and effector functions.

Our previous report showed that IL-15 does not induce transcription of XBP1s, and XBP1s does not interact with STAT5 in NK cells (Wang et al., 2019b) , suggesting that regulation of XBP1s by IL-15 is STAT5-independent. We therefore identify two novel mediators of IL-15 in NK cells, XBP1s and YTHDF2, for which XBP1s is not regulated by STAT5, while YTHDF2 is STAT5-dependent. This complexity of characterized IL-15 signaling may match the complex and pleiotropic role of IL-15, which is a key component of both the inflammatory milieu in the tumor microenvironment and the response to viral infection (Nguyen et al., 2002; Santana Carrero et al., 2019) . The complexity is also reflected in that Ythdf2 deficiency has no effect on the survival and proliferation of resting NK cells in vivo, while YTHDF2 plays a critical role in regulating proliferation and/or survival of NK cells activated by IL-15 or by MCMV infection.

Our study also supports a concept that YTHDF2 or m 6 A in general plays a more central role in NK cell dynamics in the activated state and/or disease settings.

In this study, we applied a multi-omics strategy (RNA-seq, m 6 A-seq, and RIP-seq) to identify the targets of YTHDF2 in NK cells. In line with our finding that Ythdf2-deficient NK cells showed significantly delayed cell growth, we found a large number of genes related to cell cycle and cell division that were markedly decreased in Ythdf2 ∆ NK NK cells, suggesting YTHDF2 controls cell growth by regulating cell cycle. Of note, the m 6 A modifications have been widely involved in regulating cell cycle. METTL3 promotes cell growth of AML by enhancing the translation of genes in the cell cycle pathway (Barbieri et al., 2017; Vu et al., 2017) . METTL14 deletion extends cortical neurogenesis into postnatal stages by prolonging the S to M phase transition of radial glia cells (Yoon et al., 2017) . Consistent with our study, it was reported that in HeLa cells, YTHDF2 targets pathways not only involved in molecular function but also in cell proliferation and survival (Wang et al., 2014) ; Fei et al. recently reported that YTHDF2 promoted cell proliferation possibly by facilitating mRNA degradation during cell cycle in HeLa cells (Fei et al., 2020) , suggestive of a universal mechanism(s) of YTHDF2 or its associated m 6 A modifications in maintaining cell survival and function. Because millions of cells are needed for the multi-omics strategy analysis, we had to rely on ex vivo expanded and highly proliferative NK cells. This can explain the observation that the screened targets of YTHDF2 are mainly cellcycle genes, while potential targets that control cell survival, effector function, and maturation of NK cells were not shown. Regardless, we believe our data provide the first evidence that YTHDF2 targets contribute to cell cycle and cell division processes in immune cells, particularly in NK cells.

In conclusion, we discovered a previously unknown role of YTHDF2 or m 6 A methylation as a positive regulator of NK cell anti-tumor and anti-viral activity, as well as NK cell homeostasis and maturation. These findings provide insight into how NK cells effectively survey against tumor metastases and viral infection through m 6 A mRNA methylation. 

Single-cell suspensions were prepared from the bone marrow, blood, spleen, liver, and lung of Ythdf2 Δ NK and Ythdf2 WT mice as described previously (Wang et al., 2018b) . to trace cell proliferation before transfer.

For detecting NK cell trafficking from BM to peripheral blood, 1 μ g of APC-labeled anti-CD45 antibody was i.v. injected into C57BL/6 mice. Two minutes after the antibody injection, the mice were euthanized immediately, and the BM cells were collected for flow cytometry after the cells were stained with CD3 and NK1.1 antibodies. Parenchymal NK cells were identified by lack of CD45 staining, whereas sinusoidal NK cells were identified by the presence of CD45 labeling.

Therefore, the ratio of NK cells in the sinusoids (CD45 + ) to that in the parenchymal regions (CD45 − ) indicates the NK cell trafficking from BM to peripheral blood under a steady state.

RNA was isolated using an RNeasy Mini Kit (QIAGEN) and then reverse transcribed to cDNA with PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio) following the instructions provided by the manufacturer. mRNA expression levels were analyzed using SYBR Green PCR Master Mix and a QuantStudio 12K Flex Real-Time PCR System (both from Thermo Fisher Scientific). Primer sequences are listed in Supplemental Table 1 . Immunoblotting was performed according to standard procedures, as previously described (Deng et al., 2015; Yu et al., 2006) . were analyzed by flow cytometry as described above.

The Ythdf2 HiSeq2500 machine with single read 50 bp mode. Sequencing reads were mapped to the mouse genome using HISAT2 (Version: v101) . Mapped reads of IP and input libraries were provided for R package exomePeak (Meng et al., 2014) . m 6 A peaks were visualized using IGV software (http://www.igv.org). The m 6 A binding motif was analyzed by MEME (http://meme-suite.org) and HOMER (http://homer.ucsd.edu/homer/motif). Called peaks were annotated by intersection with gene architecture using R package ChIPseeker . StringTie was used to perform expression level for mRNAs from input libraries by calculating FPKM (total exon fragments /mapped reads (millions) × exon length (kB)) (Pertea et al., 2015) . The differentially expressed mRNAs were selected with log2 (fold change) >1 or log2 (fold change) <-1 and p value < 0.05 by R package edgeR (Robinson et al., 2010) . (Li et al., 2013) . HOMER was used to find motifs of the data distribution in peak regions. Called peaks were annotated by intersection with gene and transcript architecture using ChIPpeakAnno (Zhu et al., 2010) .

Purified splenic NK cells from Ythdf2 Δ NK and Ythdf2 WT mice were cultured with IL-15 (50 ng/ml). Three days after culture, cells were treated with actinomycin D (5μg/ml, Sigma, Cat.

A9415) for the indicated time. Cells without treatment were used as 0 h. Cells were collected at the indicated time, and total RNA was extracted from the cells for qPCR. The mRNA half-life (t 1/2 ) was calculated using the method as previously described . Primer sequences are listed in Supplemental Table 1 .

We used the online resource BioGPS (http://biogps.org) to analyze the tissue-specific expression of the Ythdf2. The RNA-seq datasets GSE106138, GSE113214, and GSE25672 were downloaded from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/).

Normalized data from RNA-seq analyses were exported, and the gene-expression z-score was visualized with the Heatmap.2 function within the gplots R library.

Unpaired Student's t-tests (two-tailed) were performed using the Prism software. One-way or Two-way ANOVA was performed when three or more independent groups were compared. P values were adjusted for multiple comparisons using Holm-Sidak's procedure. A P value of < 0.05 was considered significant. *P < 0.05, **P < 0.01 and ***P < 0.001.

The RNA-seq, m 6 A-seq, and RIP-seq data were deposited in the Gene Expression Omnibus. The remaining data that support the findings of this study are available from the corresponding authors upon request. the MEK-ERK pathway in NK cells. Fig. S5 shows transcriptome-wide RNA-seq, m6A-seq, and RIP-seq assays in NK cells. Table S1 lists the primers used in this study.

This work was supported by grants from the NIH (NS106170, AI129582, CA247550, CA163205, reviewed and/or revised the paper. All authors discussed the results and commented on the manuscript.

No author has a direct conflict of interest relevant to this research to declare. shown as mean ± SD and were analyzed by unpaired two-tailed t-test (H, J, L, O), one-way ANOVA (A, B, D, E, K) , or two-way ANOVA with Sidak post-test (F, G, I). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Data are representative of at least two independent experiments.

Top 10 GO clusters from GO analysis of differentially expressed genes from RNA-seq data. 

Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors

TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression

Promoter-bound METTL3 maintains myeloid leukaemia by m(6)Adependent translation control

Interleukin-2, interleukin-15, and their roles in human natural killer cells

Control of cell cycle transcription during G1 and S phases

Molecular definition of the identity and activation of natural killer cells

A potential role for interleukin-15 in the regulation of human natural killer cell survival

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

Molecular mechanisms of natural killer cell activation in response to cellular stress

RNA N6-methyladenosine methyltransferaselike 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression

BEN/SC1/DM-GRASP, a homophilic adhesion molecule, is required for in vitro myeloid colony formation by avian hemopoietic progenitors

Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation

T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow

Transcription factor foxo1 is a negative regulator of natural killer cell maturation and function

The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells

Identification of the earliest natural killer cell-committed progenitor in murine bone marrow

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells

YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators

DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections

MDM2 controls the timely expression of cyclin A to regulate the cell cycle

Development and maturation of natural killer cells

Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest

Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase

The spindle checkpoint and chromosome segregation in meiosis

The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

Anti-tumour immunity 2 9 controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived

YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma

CREBZF as a Key Regulator of STAT3 Pathway in the Control of Liver Regeneration in Mice

Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation

HISAT: a fast spliced aligner with low memory requirements

A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif

Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection

PTEN regulates natural killer cell trafficking in vivo

2017. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways

2020. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer

RIPSeeker: a statistical package for identifying protein-associated transcripts from RIP-seq experiments

Suppression of m(6)A reader Ythdf2 promotes hematopoietic stem cell expansion

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

N (6)-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication

Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver

The transcription factor CREBZF is a novel positive regulator of p53

The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function

A protocol for RNA methylation differential analysis with MeRIP-Seq data and exomePeak R/Bioconductor package

Molecular pathways: interleukin-15 signaling in health and in cancer

Discovery of chromone-based inhibitors of the transcription factor STAT5

Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor

Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection

Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis

Unlicensed' natural killer cells dominate the response to cytomegalovirus infection

Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection

Targeting the RNA m(6)A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia

StringTie enables improved reconstruction of a transcriptome from RNA-seq reads

Interferon--a major regulator of natural killer cell-mediated cytotoxicity

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

RNA m(6) A modification enzymes shape innate responses to DNA by regulating interferon beta

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo

IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses

Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers

The RNA modification N(6)-methyladenosine as a novel regulator of the immune system

Recognition of a virus-encoded ligand by a natural killer cell activation receptor

NK cells and type 1 innate lymphoid cells: partners in host defense

The roles of interferon-gamma and perforin in antiviral immunity in mice that differ in genetically determined NK-cell-mediated antiviral activity

Homeostatic proliferation generates longlived natural killer cells that respond against viral infection

NK cell development, homeostasis and function: parallels with CD8(+) T cells

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia

)A mRNA methylation sustains Treg suppressive functions

The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells

Mettl3-mediated mRNA m(6)A methylation promotes dendritic cell activation

Loss of YTHDF2-mediated m(6)A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration

N6-methyladenosine-dependent regulation of messenger RNA stability

N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency

SMAD4 promotes TGF-beta-independent NK cell homeostasis and maturation and antitumor immunity

The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification

Divergent Role for STAT5 in the Adaptive Responses of Natural Killer Cells

)A modification controls the innate immune response to infection by targeting type I interferons

Interplay of m(6)A and H3K27 trimethylation restrains inflammation during bacterial infection

BioGPS and MyGene.info: organizing online, gene-centric information

Natural killer cells in cancer biology and therapy

CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Temporal Control of Mammalian Cortical Neurogenesis by m(6)A Methylation

ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization

Location and cellular stages of natural killer cell development

Pro-and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells

RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation

2020. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis

Control of Early B Cell Development by the RNA N(6)-Methyladenosine Methylation

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data